Dr. Maria Wanderoy, Director Drug Development

Doctoral degree in Neurochemistry and Neurotoxicology at Stockholm University. More than 25 years experiences from the pharmaceutical industry, e.g., AstraZeneca. Dr. Wanderoy has held positions ranging from global-, clinical- and preclinical project manager to senior research scientist and with that experience a broad understanding of the drug development process. She has also several years of experience as project manager for medical device development projects, for example, autoinjectors used for drug delivery in patients.

Dr Karin Franck-Larsson, medical degree and PhD in rheumatology, CMO

Medical degree and PhD in rheumatology from Uppsala University, specialist in rheumatology since year 2000. Dr. Franck-Larsson has previously held positions such as Global Medical Director Inflammation at Sobi, Head of Medical Information at the Swedish Medical Products Agency, as well as Director of Medical Affairs Nordics at Horizon Therapeutics, Raptor Pharmaceuticals, Chiesi Pharma, and Pfizer. She has also been medical advisor in rheumatology at Wyeth AB.

Dr. Anneli Hällgren, Toxicology and Safety Program

Doctoral degree in physiology at Uppsala University. More than 20 years of experience from non-clinical research and development projects in different indications and product types. Dr. Hällgren had management and other leading positions related to preclinical development and pharmacology in companies such as KaroBio and Melacure Therapeutics.

Dr. Mats Reslow, CMC

Doctoral degree in biotechnology at Lund University. More than 25 years of experience in research and development in biopharmacology and drug production. Dr. Reslow has worked as research manager at Bioglan Therapeutics AB, Skyepharma and between 2004 and 2016 as Principal Scientist at NovoNordisk A / S.

Dr. Agneta Wennerholm, Clinical Studies

Doctoral degree in clinical pharmacology at Karolinska Institutet. Dr. Wennerholm has more than 20 years of experience in pharmaceutical and biotechnology companies, academic research and clinical CRO.

Dr Johan Kolmert, Bioanalytical chemist

Received his PhD in molecular phenotyping of asthmatic patients at the Karolinska Institutet (Sweden). Dr Kolmert has nine years of experience from pre-clinical and clinical biomarker discovery at AstraZeneca R&D as a Senior Scientist. Currently, Dr Kolmert is an active senior researcher in the biology of arachidonic acid/eicosanoid-induced pulmonary inflammation at the Karolinska Institutet. He also act as independent bioanalytical consultant for small start-up pharma companies during their drug development programs.

Dr. Einar Pontén, Business development

Doctoral degree in analytical chemistry at Umeå University. CEO of Lipum to the end of 2023. Former CEO and co-founder of the chromatography company SeQuant AB for 10 years, which was acquired by Merck KGaA (Darmstadt) in 2008. Thereafter CEO of Merck SeQuant AB until 2011.

Sven Undeland, Commercial director

Master of Science (M.Sc) in Chemical and Administrative Sciences from Karlstad University. He has extensive commercial and clinical experience from the international pharmaceutical industry, through leading positions within Pharmacia, AstraZeneca and Orexo. He has primarily worked with strategic commercial support in life science projects, and he has several years of experience in business development, successfully negotiating and completing several license agreements.

About Lipum